Director/PDMR Shareholding

RNS Number : 4537D

Advanced Medical Solutions Grp PLC

15 September 2008

 



For Immediate Release                                                                                15 September 2008 

Advanced Medical Solutions Group PLC

('AMS' or the 'Company')

Dealings by Director

The Company was informed on 12 September 2008 that, on that day, Stephen Harris (Non-executive director) sold 115,000 ordinary shares of 5p each in the Company ('Ordinary Shares') at 34.5 pence per Ordinary Share.

This disposal of Ordinary Shares represented approximately 0.08 per cent. of the Company's total voting rights. 

Following this disposal, Mr Harris has a beneficial interest in 122,857 Ordinary Shares, representing approximately 0.09 per cent. of the Company's total voting rights.

The disposal is made due to personal circumstances and Mr Harris remains a committed shareholder in the company. 

This announcement is made in accordance with Rule 3.1.4 (1) (a) of the Disclosure Rules and Transparency Rules.

Enquiries

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel : [phone]
Buchanan Communications
Mark Court, Mary-Jane Johnson, Stasa Filiplic	Tel: [phone]
Landsbanki Securities (UK) Ltd	Tel: [phone]
Shaun Dobson, Claes Spång

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.

In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4% of Corpura BV in May 2008 strengthened AMS' position in hydrophilic polyurethane foam - the largest and fastest growing segment of the advanced woundcare market

AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection. 

AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.

 

END

 

 

RDSBDGDCUUBGGIU